TCGA-86-A456-01A-11R-A24H-07
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
- age_years
- 78
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.640
- INTERFERON_GAMMA_RESPONSE+0.540
- TNFA_SIGNALING_VIA_NFKB+0.480
- COAGULATION+0.380
- INFLAMMATORY_RESPONSE+0.370
- IL6_JAK_STAT3_SIGNALING+0.340
- COMPLEMENT+0.300
- XENOBIOTIC_METABOLISM+0.230
- ALLOGRAFT_REJECTION+0.220
- MYOGENESIS+0.220
Top 10 suppressed
- E2F_TARGETS-0.630
- G2M_CHECKPOINT-0.620
- MYC_TARGETS_V1-0.570
- MITOTIC_SPINDLE-0.460
- MYC_TARGETS_V2-0.400
- OXIDATIVE_PHOSPHORYLATION-0.370
- DNA_REPAIR-0.340
- MTORC1_SIGNALING-0.330
- PI3K_AKT_MTOR_SIGNALING-0.310
- GLYCOLYSIS-0.290
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 38ac1da2-32a1-4530-a553-e5adff884b4f | — | — | 0.876 |
| 2 | TCGA-MP-A4SW-01A-21R-A24X-07 | — | cohortA1 | 0.868 |
| 3 | 855f0a82-04de-485d-9613-5ccf08074069 | — | — | 0.865 |
| 4 | TCGA-EW-A3E8-01B-11R-A24H-07 | — | A | 0.857 |
| 5 | TCGA-64-1681-01A-11R-2066-07 | — | cohortA1 | 0.855 |
| 6 | ERR2598268 | fetal | fetal | 0.848 |
| 7 | MDT-AP-2283 | Med | Medulloblastoma | 0.848 |
| 8 | TCGA-97-A4M6-01A-11R-A24X-07 | — | cohortA1 | 0.847 |
| 9 | BS_KN92S7YQ | Med | Medulloblastoma | 0.846 |
| 10 | TCGA-F7-A50G-01A-11R-A266-07 | — | — | 0.843 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 27 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.640 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.540 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.480 | Inavolisib | — uncovered |
| COAGULATION | 0.380 | Binimetinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.370 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.340 | Inavolisib | — uncovered |
| COMPLEMENT | 0.300 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.230 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.220 | Idelalisib | — uncovered |
| MYOGENESIS | 0.220 | Inavolisib | — uncovered |
| APOPTOSIS | 0.210 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.190 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.180 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.130 | Remibrutinib | — uncovered |
| IL2_STAT5_SIGNALING | 0.120 | Idelalisib | — uncovered |
| PEROXISOME | 0.100 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.080 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.080 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.070 | Temsirolimus | — uncovered |
| P53_PATHWAY | 0.070 | Idelalisib | — uncovered |